Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Exp Hematol. 2011 Oct 20;40(1):22–34. doi: 10.1016/j.exphem.2011.10.003

Figure 8. A46 treatment alleviates Jak2-V617F mediated pathogenesis in vivo.

Figure 8

A. Spleen weight to body weight ratios of wild-type, vehicle treated and A46 treated MPN transgenic animals. B. Representative images of H&E stained spleen histological sections from each of these different treatment groups at 100X (Inset images: 4X). C. Quantification of the number of megakaryocytes in the spleen plotted as a function of the treatment group. D. IL-6 levels in the plasma plotted as a function of the treatment group. *p<0.05, **p<0.01.